Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide?

W P de Castro1, J V Morales, M B Wagner

  • 1Post-Graduation Program in Medical Sciences: Nephrology, Faculdade de Medicina da Universidade Federal do Rio Grande do Sul, Brazil. wcastro@portoweb.com.br

Lupus
|August 31, 2007
PubMed

Insights

Hypertension significantly impacts lupus nephritis outcomes, particularly in Afro-descendant patients. While ethnicity alone isn't a predictor, hypertension exacerbates renal function decline in this group.

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Lupus nephritis (LN) prognosis is influenced by hypertension and ethnicity.
  • Understanding these factors is crucial for effective LN management.

Purpose of the Study:

  • To investigate the impact of ethnicity and hypertension on renal function evolution in lupus nephritis patients treated with cyclophosphamide.
  • To determine if ethnicity or hypertension is the primary driver of differing renal outcomes.

Main Methods:

  • A cohort of 75 lupus nephritis patients (Caucasian and Afro-descendant) treated with cyclophosphamide was analyzed.
  • Multiple linear regression modeled the effects of ethnicity and hypertension on delta creatinine, controlling for confounders.
  • Patient characteristics, including creatinine levels, anemia, and proteinuria, were compared between ethnic groups.

Main Results:

  • Afro-descendants showed significantly higher rates of hypertension (72.2% vs. 28.1%) and anemia (66.7% vs. 31.6%) compared to Caucasians.
  • While ethnicity alone did not significantly affect renal function change (delta creatinine), hypertension showed a significant overall effect (P=0.015).
  • An interaction between hypertension and ethnicity was observed, indicating a more pronounced negative effect of hypertension on renal function in Afro-descendants (P=0.027).

Conclusions:

  • Hypertension, rather than ethnicity per se, appears to be the primary driver of worse renal function prognosis in Afro-descendant lupus nephritis patients.
  • These findings highlight the critical need to manage hypertension aggressively in Afro-descendant patients with lupus nephritis to improve renal outcomes.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...